Strong relative vaccine effectiveness was observed for each influenza strain contained in the vaccine by Seqirus (SQUS).
This includes A/H1N1 with a relative vaccine effectiveness of 29.6%.
A/H3N2 showed a relative vaccine effectiveness of 22.2%.
The B/Victoria lineages had a relative vaccine effectiveness of 29.1%.
Subgroup analyses confirmed consistently strong relative vaccine effectiveness across age groups, risk factors, and previous influenza vaccination status.
In participants aged 65 years and older, mRNA-1010 demonstrated a relative vaccine effectiveness of 27.4%.
According to the Centers for Disease Control and Prevention, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season.
Stéphane Bancel, Chief Executive Officer of Moderna, highlighted that these strong Phase 3 results mark a significant milestone in efforts to reduce the burden of influenza in older adults.
He noted that the severity of the past flu season underscores the need for more effective vaccines.